|
|
|
|
|
非在研适应症- |
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期- |
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
100 项与 Respirion Pharmaceuticals Pty Ltd. 相关的临床结果
0 项与 Respirion Pharmaceuticals Pty Ltd. 相关的专利(医药)
100 项与 Respirion Pharmaceuticals Pty Ltd. 相关的药物交易
100 项与 Respirion Pharmaceuticals Pty Ltd. 相关的转化医学